Selective oestrogen receptor modulator (SERM)
Raloxifene hydrochloride
Brand names: Evista
Adult dose
Dose: 60mg PO OD
Route: PO
Frequency: OD
Clinical pearls
- Postmenopausal osteoporosis (vertebral fractures); reduces invasive breast cancer risk
- Stop ≥3 days before prolonged immobility
Contraindications
- VTE history
- Active oestrogen-dependent cancer
- Undiagnosed vaginal bleeding
- Severe hepatic impairment
- Pregnancy
- Premenopausal women
Side effects
- Hot flushes
- Leg cramps
- VTE (esp. first 4 months)
- Stroke (in women at high CV risk)
- Endometrial benign effects
- Influenza-like symptoms
Interactions
- Cholestyramine (reduces absorption)
- Warfarin
- Levothyroxine
Monitoring
- BMD
Reference: BNF; NICE TA161; https://bnf.nice.org.uk/drugs/raloxifene-hydrochloride/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016